TORONTO, September 21, 2022 /CNW/ – Research into psychedelics shows promising advantages over existing therapies and Canada must create space for innovation in healthcare Psychedelics Canada: the non-profit trade association representing Canadian psychedelic medicine and therapy companies.
“Canada has a burgeoning psychedelics industry with the potential to improve the mental and physical health of millions of people worldwide – led by the members of our industry association,” said Nick KadyshCEO of Psychedelics Canada. “But we need federal decision-makers to make regulatory reform a priority or we risk ceding the lead to competitive countries.”
“Despite some progress Canada risks falling behind in bringing these life-changing therapies to the people who need them,” said Liam BeardCoordinator of Psychedelics Canada. “Canada must make medicinal psychedelics a public health priority – by funding research, enabling clinical trials, but most importantly, reducing the regulatory burden that slows scientific progress.
PsyCan members will be speaking to federal and provincial policymakers over the coming months about relaxing patient access requirements for psychedelic molecule treatments, improving regulatory deadlines around controlled substance licensing, and starting clinical research to to further prove the virtues of psychedelics. assisted therapies and the advancement of a secure supply chain for psychedelic molecules for scientific purposes.
PsyCan has also launched an online awareness campaign to encourage policymakers to make regulatory reform of psychedelic medicine a priority. Learn more at: psychedelicscanada.org/advocacy.
“We believe in a future where psychedelic therapies, administered by qualified physicians, are among the available treatment options for patients who could benefit,” Bedard said. “It is only by embracing innovation in mental health care that we can improve the lives of Canadians.”
ABOUT PSYCHEDELICS CANADA
Psychedelics Canada, incorporated as the Psychedelics Businesses Association, is the not-for-profit trade association of the legal psychedelics industry. Psychedelics Canada is dedicated to working together to advance government regulation, scientific research and the specific needs of the legal psychedelics industry. Psychedelics Canada member companies are dedicated to collective action and motivated by a belief in the promise of psychedelic molecules as therapeutic treatments. The member companies represent research, development, manufacturing and clinical operations. At the time of its inception, Psychedelics Canada was the world’s premier national-level trade association for the legal psychedelics industry.
SOURCE Psychedelics Canada
For more information: Liam Bedard, Coordinator, Psychedelic Businesses Association, acting as Psychedelics Canada, email: [email protected]Telephone: 011 32 468 37 85 90
